Business   

Cadila to launch blockbuster combination drug

— PHOTO: S. SUBRAMANIUM

HEART CARE: Indravadan Modi (right), Chairman, Cadila Pharmaceuticals, and Salim Yusuf, cardiologist, unveil ‘Polycap’, the drug combination which reduces the risk of heart disease, in New Delhi on Saturday.

NEW DELHI: Ahmedabad-based Cadila Pharmaceuticals on Saturday said it was expecting Rs. 100 crore revenue from the sale of its patented combination drug, Policap, which would be launched by the middle of next month.

The company has sought permission from the Drug Controller General of India to launch the drug here and is hopeful that it may get the same by mid-June.

Policap is a combination of three common anti-hypertensive drugs along with aspirin and statin (cholesterol lowering drug) and can reduce risk of heart attacks by half.

“Policap has the potential of becoming a blockbuster drug and revenue earnings from it should be more than Rs. 100 crore annually,” Cadila Pharmaceuticals Chairman Indravadan Modi told reporters here. The drug had been tested on over 200 patients in 50 centres across the country, Mr. Modi said, adding that studies revealed that the risk of heart attack could be decreased by 50 per cent with the use of this drug.

The company is soon going to apply for regulatory approvals to introduce the drug in the U.S. and other developed markets.

Cadila is also looking at global tie-ups with multinationals to launch the drug in overseas markets. “We are talking to many international players but it is too early to comment anything on that,” Modi said. — PTI

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

SBI net up 36 % at Rs. 9,121 cr
Signs of recovery in manufacturing
IndusInd to focus on 4 themes
Cadila to launch blockbuster combination drug

Copyright © 2009, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu